Correlation Engine 2.0
Clear Search sequence regions


The effect of gemfibrozil is mediated by the activation of peroxisome proliferator-activated receptor alpha (PPAR alpha). The objective of this study was to determine whether the lipid response to gemfibrozil therapy is influenced by the PPAR alpha-L162V polymorphism. Sixty-three abdominally obese men were randomly assigned to a 6-month-intervention program with either receiving a placebo (N = 31) or gemfibrozil (N = 32). In response to gemfibrozil therapy, L162-homozygotes exhibited a 5.5% increase in high-density lipoprotein 2 cholesterol (HDL(2)-C) levels compared with a 50.0% increase among carriers of the V162 allele (P = 0.03). These results suggest that the HDL(2)-C response to gemfibrozil is modulated by the PPAR alpha-L162V polymorphism.

Citation

Yohan Bossé, Agnès Pascot, Martine Dumont, Martin Brochu, Denis Prud'homme, Jean Bergeron, Jean-Pierre Després, Marie-Claude Vohl. Influences of the PPAR alpha-L162V polymorphism on plasma HDL(2)-cholesterol response of abdominally obese men treated with gemfibrozil. Genetics in medicine : official journal of the American College of Medical Genetics. 2002 Jul-Aug;4(4):311-5

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 12172398

View Full Text